Medimix Hematology
  • Home
  • Live from the congress
    • 2025
      • EBMT 2025
    • 2024
      • ASH 2024 (San Diego)
      • EHA 2024 (Madrid)
      • ASCO 2024 (Chicago)
  • Contact
  • Other specialties
    • Dermatology
    • Oncology
  • SIGN UP
  • SIGN IN
    • Login
ASCO 2024

Multiple myeloma – DREAMM-7 update

June 12, 2024

Presented by Prof Claudio Cerchione (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Italy)

Prof Claudio Cerchione, haematologist at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy, one of the authors of the DREAMM7 study, gave a summary of the main outcomes of the study presented at ASCO24.

In the DREAMM-7 clinical trial, the combination of belantamab mafodotin with bortezomib and dexamethasone (BVd) exhibited a statistically significant and clinically meaningful PFS advantage compared to the standard-of-care regimen of daratumumab, bortezomib and dexamethasone (DVd) in patients with RRMM who had received at least one prior line of treatment. The PFS was 36.6 months in the experimental BVd arm versus 13 months in the DVd control group. At ASCO, subgroup analyses were presented, confirming a consistent benefit across all prespecified subgroups, including patients refractory to lenalidomide and patients with one or more high-risk cytogenetic abnormalities. These findings, demonstrating significant efficacy in subgroups with high unmet medical needs, support the potential of BVd as a new standard of care in this clinical setting.

References:

Matteos MV, ASCO24, #7503

With the educational support of:

Tags:

in-depth

Share Article

Medimix Hematology

Website created by MediMix © 2025 - Privacy Policy

  • Home
  • Live from the congress
    • 2025
      • EBMT 2025
    • 2024
      • ASH 2024 (San Diego)
      • EHA 2024 (Madrid)
      • ASCO 2024 (Chicago)
  • Contact
  • Other specialties
    • Dermatology
    • Oncology
  • SIGN UP
  • SIGN IN
    • Login
    • Logout